Pharmacokinetics/pharmacodynamics of antiviral agents used to treat SARS-CoV-2 and their potential interaction with drugs and other supportive measures: a comprehensive review by the PK/PD of anti-infectives study group of the European Society of Antimicrobial Agents

Full item page Simple item page

  • dc.contributor.author Zeitlinger, Markus
  • dc.contributor.author Koch, Birgit C.P.
  • dc.contributor.author Bruggemann, Roger
  • dc.contributor.author De Cock, Pieter
  • dc.contributor.author Felton, Timothy
  • dc.contributor.author Hites, Maya
  • dc.contributor.author El, Jennifer
  • dc.contributor.author Luque Pardos, Sònia
  • dc.contributor.author MacGowan, Alasdair P.
  • dc.contributor.author Marriott, Deborah J. E.
  • dc.contributor.author Muller, Anouk E.
  • dc.contributor.author Nadrah, Kristina
  • dc.contributor.author Paterson, David L.
  • dc.contributor.author Standing, Joseph F.
  • dc.contributor.author Telles, João P.
  • dc.contributor.author Wölfl-Duchek, Michael
  • dc.contributor.author Thy, Michael
  • dc.contributor.author Roberts, Jason A.
  • dc.contributor.author PK/PD of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology, Infectious Diseases (ESCMID)
  • dc.date.accessioned 2020-10-07T06:37:20Z
  • dc.date.available 2020-10-07T06:37:20Z
  • dc.date.issued 2020
  • dc.description.abstract There is an urgent need to identify optimal antiviral therapies for COVID-19 caused by SARS-CoV-2. We have conducted a rapid and comprehensive review of relevant pharmacological evidence, focusing on (1) the pharmacokinetics (PK) of potential antiviral therapies; (2) coronavirus-specific pharmacodynamics (PD); (3) PK and PD interactions between proposed combination therapies; (4) pharmacology of major supportive therapies; and (5) anticipated drug-drug interactions (DDIs). We found promising in vitro evidence for remdesivir, (hydroxy)chloroquine and favipiravir against SARS-CoV-2; potential clinical benefit in SARS-CoV-2 with remdesivir, the combination of lopinavir/ritonavir (LPV/r) plus ribavirin; and strong evidence for LPV/r plus ribavirin against Middle East Respiratory Syndrome (MERS) for post-exposure prophylaxis in healthcare workers. Despite these emerging data, robust controlled clinical trials assessing patient-centred outcomes remain imperative and clinical data have already reduced expectations with regard to some drugs. Any therapy should be used with caution in the light of potential drug interactions and the uncertainty of optimal doses for treating mild versus serious infections.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Zeitlinger M, Koch BCP, Bruggemann R, De Cock P, Felton T, Hites M. et al. Pharmacokinetics/pharmacodynamics of antiviral agents used to treat SARS-CoV-2 and their potential interaction with drugs and other supportive measures: a comprehensive review by the PK/PD of anti-infectives study group of the European Society of Antimicrobial Agents. Clin Pharmacokinet. 2020 Jul 28: 1–22. DOI: 10.1007/s40262-020-00924-9
  • dc.identifier.doi http://dx.doi.org/10.1007/s40262-020-00924-9
  • dc.identifier.issn 0312-5963
  • dc.identifier.uri http://hdl.handle.net/10230/45414
  • dc.language.iso eng
  • dc.publisher SpringerOpen
  • dc.rights This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
  • dc.subject.other COVID-19 (Malaltia) -- Tractament
  • dc.subject.other Medicaments -- Administració
  • dc.subject.other Medicaments antivírics
  • dc.title Pharmacokinetics/pharmacodynamics of antiviral agents used to treat SARS-CoV-2 and their potential interaction with drugs and other supportive measures: a comprehensive review by the PK/PD of anti-infectives study group of the European Society of Antimicrobial Agents
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Collections

Articles (Hospital del Mar Research Institute)